Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology
Disparities in Cancer Care
,
Conference Highlights ASCO
ASCO 2021 Presidential Address: Eliminating Disparities in Cancer Care
Wayne Kuznar
Read More
Conference Highlights ASCO
,
Lung Cancer
Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC
Phoebe Starr
Read More
Value-Based Care
,
Conference Highlights ASCO
Rapid Biosimilar Adoption Possible in Community Oncology Practice
Chase Doyle
Read More
Multiple Myeloma
,
Conference Highlights ASCO
New CAR T-Cell Therapy Produces Durable Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Read More
FDA Approvals
,
Leukemia
,
Lymphoma
,
Conference Highlights ASCO
Rylaze FDA Approved as Part of a Treatment Regimen for Pediatric Leukemia and Lymphoma
Read More
Cholangiocarcinoma
,
FDA Approvals
,
Conference Highlights ASCO
Truseltiq Second Targeted Therapy Approved for Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations
Read More
FDA Approvals
,
Multiple Myeloma
,
Conference Highlights ASCO
FDA Approves Darzalex Faspro plus Pomalyst and Dexamethasone for Multiple Myeloma
Read More
FDA Approvals
,
Conference Highlights ASCO
FDA Approves Avapritinib for Advanced Systemic Mastocytosis
Read More
FDA Approvals
,
Conference Highlights ASCO
Pembrolizumab plus Lenvatinib Combination Receives Regular Approval for Advanced Endometrial Carcinoma
Read More
FDA Approvals
,
Urothelial Cancer
,
Conference Highlights ASCO
Padcev Receives Regular FDA Approval for Locally Advanced or Metastatic Urothelial Cancer
Read More
1
2
Page 1 of 2
Results 1 - 10 of 14